心力衰竭中静脉注射铁 铁缺乏症患者:随机对照试验的元分析
Yangguang Liu1, Jiahuan Li1, Yingwen Chen1
1Department of Cardiology, The Eighth Affiliated Hospital, Southern Medical University (The First People's Hospital of Shunde, Foshan), Foshan, China.
Journal of evidence-based medicine
|August 14, 2025
概括
静脉注射铁疗法显著减少了铁缺乏症 (ID) 的心力衰竭 (HF) 患者的住院和心血管死亡. 它还可以提高运动能力,特别是在转林和低或缺血性心脏病患者中.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 缺铁 (ID) 在心力衰竭 (HF) 患者中很普遍,但静脉注射铁疗法的疗效仍在争论中.
- 在HF中治疗ID的最佳治疗策略对于改善患者的治疗结果至关重要.
研究的目的:
- 系统评估静脉注射铁治疗对心力衰竭和铁缺乏症患者临床结果和运动能力的影响.
- 确定可能从这种干预中受益最多的患者子组.
主要方法:
- 进行了一项全面的元分析,包括14项随机对照试验,共计7786名参与者.
- 用随机效应模型分析数据,以合成住院,心血管死亡和运动能力等结果.
主要成果:
- 静脉注射铁疗法显著降低了复合事件的风险 (HF住院和心血管死亡),HF住院和心血管死亡.
- 通过6分钟步行测试测量的运动能力显著改善.
- 转林和率<20%的患者和患有缺血性心脏病的患者的益处更为明显.
结论:
- 静脉注射铁疗法有效地减少了ID的HF患者的住院和心血管死亡.
- 它还可以增强运动能力,为具有特定特征的患者提供更大的好处,如低TSAT或缺血性心肌病.
相关概念视频
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Heart Failure Drugs: Inotropic Agents
722
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
722
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure III: Clinical Manifestations
45
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
45
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508


